The company, founded and incubated by MPM Capital, has proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. These radiopharmaceuticals are designed for high tumor penetration and long residence time, minimizing side effects of treatment and enabling clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Aktis Oncology's innovative approach could potentially revolutionize cancer treatment by offering a more targeted and effective therapy for patients with solid tumor cancers.